NCT04468932 Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy
| NCT ID | NCT04468932 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oregon Health and Science University |
| Condition | Palsy Supranuclear |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2020-01-17 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2020-01-17 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this proposal is to investigate the effect of non-invasive repetitive cerebellar transcranial magnetic stimulation (rTMS) on motor control in progressive supranuclear (PSP). The central hypothesis is that augmenting cerebellar inhibition via cerebellar rTMS will decrease postural instability in patients with PSP. We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS.
Eligibility Criteria
Inclusion Criteria: * probable or possible PSP by the revised MDS PSP Criteria (Hoglinger 2017) * age 40-85 at time of screening * ability to understand and cooperate with simple instructions in English * ability to read at 6th grade reading level in English * ability to stand unassisted for at least 30 seconds and to be able walk independently with a walker * ability to refrain from new physical and speech therapy programs for the duration of the study * ability to remain on stable doses of any cholinergic, dopaminergic, serotonergic sedative or NMDA receptor antagonists for the duration of the study * females of child-bearing age must perform a urine pregnancy test and be on reliable birth control during the course of the study Exclusion Criteria: * other significant neurological or vestibular disorders * presence of electrically, magnetically or mechanically activated implants or history of injurious metal exposure in eyes, head, or body
Contact & Investigator
Marian L Dale, MD, MCR
PRINCIPAL INVESTIGATOR
Oregon Health and Science University
Frequently Asked Questions
Who can join the NCT04468932 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Palsy Supranuclear. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04468932 currently recruiting?
Yes, NCT04468932 is actively recruiting participants. Contact the research team at balance@ohsu.edu for enrollment information.
Where is the NCT04468932 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT04468932 clinical trial?
NCT04468932 is sponsored by Oregon Health and Science University. The principal investigator is Marian L Dale, MD, MCR at Oregon Health and Science University. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.